Editas Medicine
Editas Medicine is a leading gene editing company focused on developing CRISPR medicines for people with serious diseases.
Research and Pipeline | Editas Medicine
Editas Medicine works with two distinct CRISPR nucleases: Cas9 and Cas12a (also known as Cpf1). Both nucleases have distinct gene editing and targeting capabilities.
Who We Are | Editas Medicine
Editas Medicine is a pioneering gene editing company focused on developing transformative medicines, translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of medicines for …
CRISPR Gene Editing - Editas Medicine
Editas Medicine is a leading gene editing company dedicated to developing a robust pipeline of medicines to treat people living with serious diseases around the world. We have built a platform that utilizes CRISPR gene editing, a revolutionary approach to developing medicines.
Newsroom - Editas Medicine
Nov 4, 2024 · Access the latest press releases and other information from Editas Medicine, a leading gene editing company dedicated to developing CRISPR medicines for people living with serious diseases around the world.
Editas Medicine Announces Third Quarter 2024 Results and …
Nov 4, 2024 · Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University
Information for Patients | Editas Medicine
Oct 18, 2023 · Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of medicines for people living with serious diseases around the world.
Contact Us - Editas Medicine
Get in touch with Editas Medicine, a leading gene editing company dedicated to developing CRISPR-based medicines for people living with serious diseases around the world.
Editas Medicine to Present at the 43rd Annual J.P. Morgan …
Jan 6, 2025 · As a leading gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of in vivo medicines for people living with serious diseases around the world.
Editas Medicine and Shoreline Biosciences Enter into Definitive ...
Jan 19, 2023 · As part of the transaction, Shoreline will acquire EDIT-202, Editas Medicine’s preclinical multiplexed edited iNK cell medicine for the potential treatment of solid tumors, as well as an additional iNK program under development and certain related manufacturing technologies.